Source comparison
Sexual Function vs Photoprotection: The Mechanism Doesn't Support Stacking
PT-141's libido-enhancing effect is mediated entirely through central MC4R activation in the paraventricular nucleus of the hypothalamus. It doesn't require peripheral melanocortin signalling to function. Melanotan-2's pigmentation effect is mediated entirely
This comparison does not assign a generated winner or score.
- PT-141's libido-enhancing effect is mediated entirely through central MC4R activation in the paraventricular nucleus of the hypothalamus. It doesn't require peripheral melanocortin signalling to function. Melanotan-2's pigmentation effect is mediated entirely through peripheral MC1R activation in epidermal melanocytes. It doesn't require CNS penetration to darken skin. The pathways are anatomically separate, but the receptor targets are biologically redundant because both peptides activate melanocortin receptors systemically regardless of their intended site of action.
- Research conducted at the University of Arizona's College of Medicine found that Melanotan-2 produces mild central MC4R activation at doses above 500 mcg, creating measurable but clinically insignificant effects on sexual arousal. Not enough to justify its use as a libido agent, but enough to compound nausea and flushing when stacked with PT-141. Conversely, PT-141 produces weak MC1R activation in melanocytes, contributing to transient skin darkening in some users but at levels far below therapeutic pigmentation thresholds.
- The honest answer: if sexual function is the goal, PT-141 monotherapy at 1.75–2 mg delivers maximal MC4R activation without peripheral melanocortin burden. If photoprotection is the goal, Melanotan-2 at 250–500 mcg achieves melanogenesis without CNS side effects. Stacking both assumes the mechanisms are additive. They're not. They're overlapping, which means the side effect profile compounds while the intended effects plateau.
- PT-141 (Bremelanotide)
- MC4R (central)
- Hypothalamus, area postrema, brainstem
- 2.7 hours
- Nausea 38%, flushing 28%, hypertension 18%
- Selective for libido enhancement; CNS penetration creates nausea liability
- Melanotan-2
- MC1R (peripheral)
- Melanocytes, vascular smooth muscle
- 33 minutes
- Nausea 35%, flushing 42%, erections (unintended) 22%
- Non-selective melanocortin agonist; broad receptor activation
- Stacked (PT-141 + MT-2)
- MC1R, MC3R, MC4R, MC5R
- Systemic
- Variable
- Nausea 68%, flushing 61%, hypertension 29%
- Redundant melanocortin signalling; adverse events compound without synergy